The Zacks Analyst Blog Highlights:Covidien, Horizon Pharma, Johnson and Johnson, CR Bard and Becton, Dickinson

News provided by

Jun 20, 2012, 09:30 ET

CHICAGO, June 20, 2012 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Covidien (NYSE:COV), Horizon Pharma, Inc. (Nasdaq:HZNP), Becton, Dickinson and Company (NYSE:BDX), Johnson and Johnson (NYSE:JNJ) and CR Bard Inc. (NYSE:BCR).

(Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO)

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Tuesday's Analyst Blog:

Covidien Teams Up with Horizon

On June 18, 2012, Mallinckrodt, the Pharmaceuticals business of Covidien (NYSE:COV) revealed that it had inked a definitive co-promotion agreement with Horizon Pharma, Inc. (Nasdaq:HZNP), a biopharmaceutical company. As per the agreement, Mallinckrodt will promote DUEXIS (ibuprofen and famotidine) in the U.S. through December 14, 2014. The agreement includes the possibility of renewal for additional periods.

As per the understanding between the companies, Mallinckrodt will receive compensation for every prescription generated according to the physician promotion targets agreed upon. The promotion of DUEXIS to physicians is expected to begin from August 2012. However, Horizon will continue to be the exclusive manufacturer and supplier of DUEXIS and record its revenue.

DUEXIS is a single tablet combination, indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis. It also reduces the risk of developing ulcers in the upper gastrointestinal tract. It has been available to U.S. physicians since December 2011 and was fully launched in January 2012.

Though the sales force at Horizon since the launch of DUEXIS performed satisfactorily, the significant promotional efforts by Mallinckrodt are expected to yield improved results. Management at Horizon is optimistic about the co-promotion agreement expanding its market reach amongst primary care physicians in the U.S.

The agreement will take some weight off the sales and marketing expenses of Horizon, which had increased almost ten-fold to $11.0 million in the first quarter, primarily due to increased marketing, advertising and promotional efforts for DEUXIS. The commercialization strategy also includes employment of an additional 80 sales representatives to build up its sales force, to drive the DUEXIS revenue.

Horizon is rigorously bolstering the sales of its proprietary DUEXIS. The company generated 41% net sales from the tablet. Considering the company's therapeutic focus on pain management, osteoarthritis, rheumatoid arthritis and gastro-intestinal side-effects, DUEXIS has the potential to become its flagship product.

The agreement provides Mallinckrodt's sales forces the right to sell DUEXIS in the U.S. market. Management at Covidien believes that the co-promotion agreement represents a key opportunity for its pharmaceuticals business as Mallinckrodt prepares to spin off the next year, as announced in December 2011.

The addition of DUEXIS to its portfolio will boost Covidien's efforts to improve standards of care. DUEXIS is thus expected to be an excellent accompaniment to Covidien's existing portfolio of pain relief products.

Covidien is a leading developer, manufacturer and distributor of medical devices and services on a global scale. Its business segments overlap with the business of its competitors such as Becton, Dickinson and Company (NYSE:BDX), Johnson and Johnson (NYSE:JNJ) and CR Bard Inc. (NYSE:BCR) among others. While acquisitions remain the most important part of the company's growth strategy, the agreement reflects its aggressive strategy of portfolio extension.

The stock currently retains a Zacks #3 Rank, which translates into a short-term Hold rating. This is in agreement with our long-term Neutral recommendation.

Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5515.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518.

Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
[email protected]
http://www.zacks.com

SOURCE Zacks Investment Research, Inc.